| | |
C.H. Unnikrishnan 11:04 PM | August 26,2009
The promoters will also benefit from a non-compete clause signed with US firm Abbot Laboratories
|
|
Priyal Guliani and Vidhi Godiawala / CNBC TV18 10:05 PM | May 05,2009
The scheme, which was due to mature on Tuesday, had an exposure of Rs10.95 crore to IL&FS Trust Co. Ltd-Wockhardt-GE Financial Services’ debt paper
|
|
C.H. Unnikrishnan and Radhieka Pandeya 12:34 AM | April 20,2009
Average growth in sales for the quarter likely to be less than 11%, compared with 14% in the year-ago period
|
|
Saikat Chatterjee / Bloomberg 10:42 PM | April 01,2009
The company had net debt of about Rs3,400 crore in the year ended 31 December, pegging the company’s debt-to-equity ratio at 2.3 times
|
|
C.H. Unnikrishnan 10:51 PM | December 02,2008
Eli Lilly’s petition against Aurobindo was also filed on the same day on charges of Cymbalta patent infringement
|
|
01:29 AM | April 29,2008
Companies are not taken to task for misleading statements
|
|
Seema Singh 11:36 AM | April 25,2008
India is setting up a national biotechnology regulatory authority on the lines of the US Food and Drug Administration, which will start regulating the industry in two years,
|
|
C.H. Unnikrishnan 01:07 AM | July 26,2007
The case was filed by the 23 medical representatives who were fired and the FMRAI, an association of sales people at pharmaceutical companies
|
|